CSIMarket Company Name, Ticker, Industry, else..
 
Glycomimetics Inc   (NASDAQ: GLYC)
Other Ticker:  
 
 
Price: $0.2929 $-0.01 -3.013%
Day's High: $0.32 Week Perf: -2.69 %
Day's Low: $ 0.28 30 Day Perf: -28.56 %
Volume (M): 939 52 Wk High: $ 3.53
Volume (M$): $ 275 52 Wk Avg: $1.21
Open: $0.29 52 Wk Low: $0.14



 Market Capitalization (Millions $) 19
 Shares Outstanding (Millions) 64
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) 0
 Cash Flow (TTM) (Millions $) -35
 Capital Exp. (TTM) (Millions $) 0

Glycomimetics Inc
Glycomimetics Inc. is a biopharmaceutical company that focuses on the discovery and development of glycomimetic drugs. Glycomimetics are synthetic compounds that mimic carbohydrates, which play a crucial role in various biological processes. The company's research and development efforts primarily target diseases and conditions that involve inflammation, cell adhesion, and glycoprotein-dependent signaling. Some of the therapeutic areas Glycomimetics Inc. focuses on include blood disorders, oncology, and inflammatory diseases. The company aims to leverage its expertise in glycomimetics to develop novel and effective treatments for patients in need.


   Company Address: 9708 Medical Center Drive Rockville 20850 MD
   Company Phone Number: 243-1201   Stock Exchange / Ticker: NASDAQ GLYC


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
AGIO   -22.59%    
BPMC   -1.17%    
KZR   -0.86%    
STTK        4% 
SYRS   -2.72%    
URGN   -3.37%    
• View Complete Report
   



Business Update

GlycoMimetics Undertakes Strategic Review After Pivotal Phase 3 AML Study Results, Announces Key Opinion Leader...

Published Thu, Jul 25 2024 4:47 PM UTC

Rockville, Md., Current Date GlycoMimetics, Inc. (Nasdaq: GLYC), a late clinical-stage biotechnology company renowned for its glycobiology-based therapies targeting cancers and inflammatory diseases, has unveiled a comprehensive strategy that includes a corporate restructuring plan and a strategic review. This decision is catalyzed by pivotal study results and a continued...
Business Update

GlycoMimetics Reports Promising Results from Phase 3 Study of Uproleselan in Relapsed/R...

Published Thu, May 30 2024 12:38 AM UTC

GlycoMimetics, a leading biotechnology company focused on developing innovative glycobiology-based therapies for cancers and inflammatory diseases, recently announced its plans to host a key opinion leader event to present the comprehensive results of its pivotal Phase 3 study on uproleselan. This investigational drug holds tremendous potential in the treatment of relapsed/r...
Business Update

Unraveling the Efficacy of Uproleselan in Relapsed/Refractory Acute Myeloid Leukemia: I...

Published Wed, May 29 2024 10:38 PM UTC

In the realm of oncology and inflammatory diseases, advancements in glycobiology-based therapies have shown promising potential. GlycoMimetics, a late clinical-stage biotechnology company, has been at the forefront of discovering and developing these novel therapies. Recently, GlycoMimetics announced a key opinion leader event scheduled for June 4, 2024, aimed at providing a...
Glycomimetics Inc

1 Major Pharmaceutical Preparations Company Faces Contraction in Business Conduct Through First Quarter of 2024.

The Major Pharmaceutical Preparations industry continues to release results during the reporting season, with many corporations disclosing their financial performance for the first quarter of 2024. Among them is Glycomimetics Inc (GLYC), a rising company in the biotechnology sector. The company reported an operating shortfall of $-11.115027 million for the most recent fiscal period, indicating a challenging quarter.
Although Glycomimetics Inc has not yet announced its revenue for the period, it is important to analyze the company's efforts in the first quarter of 2023 to provide some perspective. During that time, the company booked an operating shortfall of $-10.941018 million, suggesting a slight increase in the current fiscal year.
Business Update

Uproleselan Falls Short in Phase 3 Study for Relapsed/Refractory Acute Myeloid Leukemia

Published Mon, May 6 2024 1:47 PM UTC

In a recent announcement, biotechnology company GlycoMimetics, Inc. shared the topline results of its pivotal Phase 3 study evaluating the efficacy of uproleselan in 388 patients diagnosed with relapsed/refractory acute myeloid leukemia (R/R AML). Despite hopes for a breakthrough, the combination of uproleselan with chemotherapy did not demonstrate a statistically significan...









Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com